Ravuconazole

DB06440InvestigationalSmall molecule

Investigated for use/treatment in fungal infections, aspergillosis, candidiasis, and onychomycosis.

Chemical structure of Ravuconazole
Mechanism
Curator reviewed
Primary indication
Investigated for use/treatment in fungal infections, aspergillosis, candidiasis, and onychomycosis.Curator reviewed
Formula / weight
C22H17F2N5OS · 437.47 g/mol (avg)
Code names
BMS-207147 · ER-30346

Resolves to

Compound
UNII95YH599JWVCAS182760-06-1ChEMBLCHEMBL294029ChEBI143825PubChem467825KEGGD02556
Structure
InChIKeyOPAHEYNNJWPQPX-RCDICMHDSA-NSMILESC[C@@H](C1=NC(=CS1)C1=CC=C(C=C1)C#N)[C@](O)(CN1C=NC=N1)C1=CC=C(F)C=C1F
Targets
P10613ERG11

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
124Drug interactionsStructured to mechanism, not free text
Sign in
4Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Ravuconazole, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In